<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Manifold Bio — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Biotech / Drug Discovery</span>
    <h1>136. Manifold Bio</h1>
    <p class="meta">Protein Barcoding for Rapid In Vivo Drug Testing</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Manifold Bio</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>George Church & Gleb Kuznetsov</strong></p><p>Wyss Institute / Harvard Medical School</p><p>Dr. Church is a pioneering geneticist; Gleb Kuznetsov developed protein barcoding technology for multiplexed drug candidate testing</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>Manifold Bio uses proprietary protein barcoding technology to enable testing of hundreds of drug candidates simultaneously in a single animal study. By attaching unique molecular barcodes to protein therapeutics, Manifold can track the behavior of many candidates in parallel, dramatically accelerating the drug discovery process while reducing animal use and costs. This multiplexed approach can compress years of traditional sequential testing into months.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series A — $40M</strong> — Expanding protein barcoding platform and pharma partnerships.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio and George Church lab spinout research.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>10-100x acceleration:</strong> Multiplexed testing dramatically compresses drug discovery timelines.</li><li><strong>Church lab innovation:</strong> World-class scientific pedigree and continued collaboration.</li><li><strong>Ethical benefits:</strong> Reduces animal use while improving data quality.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Platform adoption:</strong> Pharma companies may be slow to adopt new discovery paradigms.</li><li><strong>Protein-focused:</strong> Technology currently applies to protein/biologic drugs, not small molecules.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What types of protein therapeutics are best suited for your barcoding approach?</li><li>How many pharma partnerships have you established and what's the typical engagement model?</li><li>What is the typical project timeline and cost savings vs. traditional discovery?</li><li>Are you developing internal drug programs or purely a platform company?</li><li>How do you see AI/ML integration enhancing your platform capabilities?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Multiplexed Drug Discovery Innovation</p>
      <p>Hi Gleb,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following Manifold Bio's innovative protein barcoding approach with great interest. The ability to test hundreds of drug candidates simultaneously in a single study represents a fundamental advancement in how drugs are discovered — faster, cheaper, and with fewer animals. This is exactly the kind of platform technology from Dr. Church's lab that we find compelling.</p>
      <p>Would you be open to a brief conversation about Manifold's journey from Wyss Institute research to pharma partnerships? We'd love to learn more and explore how HUCP might support your growth.</p>
      <p>Looking forward to connecting.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
